Across TCGA pan-cancer cohorts, SNORD116-11 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SNORD116-11 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SNORD116-11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNORD116-11 expression acts as an unfavorable survival marker.

LUSC, LUAD, and CHOL are the cancer types where SNORD116-11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.350	0.728	.021	9	view →
LUAD	DFS	Median	All	0.244	0.791	.007	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SNORD116-11 tumor-vs-normal RNA expression · all SNORD116-11 data types